ramipril

Ligand id: 6339

Name: ramipril

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ramipril

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 95.94
Molecular weight 416.23
XLogP 4.92
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the management of mild to severe hypertension. In March 2013 the EMA granted orphan designation for ramiprilat for the treatment of Stargardt’s disease. There is no pan-European full approval for this drug, although individual national approval agencies have granted marketing authorisation.
Mechanism Of Action and Pharmacodynamic Effects
Converted to active metabolite ramiprilat, which competes with the binding of angiotensin I to angiotensin-converting enzyme therefore reducing conversion of angiotensin I to angiotensin II. Decreased levels of angiotensin II result in a decrease in blood pressure.
External links